Strengthen CMC Strategy to Prevent Downstream Delays

Many CMC challenges that emerge during manufacturing originate much earlier in development. They are decisions made months earlier, in cell line development, process design or formulation, without a clear picture of what they would cost downstream. By the time the consequences show up, the options for fixing them are expensive, time-consuming and need regulatory approvals. This webinar gives biologics teams the real-world perspective and practical frameworks to make those decisions with confidence.
The session examines where CMC strategy most commonly breaks down. Across cell line development, process design, formulation, analytics, manufacturing and tech transfer, there are recurring decision points that teams underestimate. The strategic implications are rarely made visible early enough, and by the time they surface, the cost of course-correcting is already high.
The featured speakers will share lessons from more than 25 years of CMC experience, including recurring development patterns, decisions that initially appeared low risk and early indicators that distinguish programs positioned to scale from those likely to stall. The session will connect these strategic insights with structured, stage-appropriate development pathways.
Different programs have different needs. A team racing to first-in-human has fundamentally different CMC priorities than one preparing for a phase transition or optimizing an underperforming process. The webinar will show how to match CMC strategy to program stage and goals, and how structured development frameworks can translate strategic thinking into practical development paths.
Whether attendees are developing an initial CMC strategy, preparing for technology transfer or restoring momentum to a stalled program, this session will provide practical guidance for making informed decisions and reducing downstream risk.
Register for this webinar to learn how CMC strategy can reduce costly rework, development delays and manufacturing risk.

Who Should Attend
This webinar will appeal to:
CMC Leads, Directors and Strategists in biotech and pharma
Process Development and Manufacturing professionals involved in biologics programs
Business Development and Licensing professionals evaluating CDMO partnerships
Biotech Founders and Program Managers navigating early-stage development decisions
CMC and Bioprocess Development professionals
Manufacturing and Operations Managers in biotech
Research, Nonclinical and Clinical Development teams
Regulatory Affairs professionals
Technical Operations leaders preparing for regulatory submission, phase transitions or tech transfer

What You Will Learn
Attendees will gain insights into:
Where CMC strategy breaks down and why problems often surface later
Which early CMC decisions have the greatest downstream impact
How to align CMC strategy with program stage
What stage-appropriate CMC support looks like in practice, from first-in-human to phase transition

Register free on Xtalks:
https://xtalks.com/webinars/strengthen-cmc-strategy-to-prevent-downstream-delays/